How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 62.8 | 62.8 | 63.3 | 63.6 | 63.6 | 63.6 | +0.8 |
| Healthcare | 24.1 | 24.1 | 22.8 | 23.7 | 23.7 | 24.2 | +0.1 |
| Chemicals | 3.5 | 3.5 | 3.8 | 4.4 | 4.4 | 4.2 | +0.7 |
| FMCG | 7.1 | 7.1 | 4.9 | 2.6 | 2.6 | 2.8 | -4.3 |
| Unclassified | 1.6 | 1.6 | 1.7 | 1.6 | 1.6 | 2.5 | +0.9 |
| Defence | · | · | · | 0.6 | 0.6 | 0.3 | -0.3 |
| Financial Services | · | · | · | 0.9 | 0.9 | · | 0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| DIVISLAB | Pharma | 8.40% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| APOLLOHOSP | Healthcare | 6.71% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| AUROPHARMA | Pharma | 6.52% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| SUNPHARMA | Pharma | 6.36% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| PPLPHARMA | Pharma | 6.04% | 6 | 1 | 5 | 4 | 6 | 0/2 | +14.5% |
| TORNTPHARM | Pharma | 5.26% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| NEULANDLAB | Healthcare | 4.59% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| EMCURE | Pharma | 4.36% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| MAXHEALTH | Healthcare | 4.16% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| FORTIS | Healthcare | 3.25% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| ZYDUSWELL | FMCG | 2.82% | 7 | 2 | 3 | 8 | 2 | 0/2 | +13.4% |
| IPCALAB | Pharma | 2.43% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| VIJAYA | Pharma | 2.36% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| NAVINFLUOR | Chemicals | 2.17% | 9 | 10 | 3 | 9 | 1 | 0/2 | +21.1% |
| LAURUSLABS | Pharma | 2.14% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| GLENMARK | Pharma | 1.73% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| GLAXO | Healthcare | 1.65% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| LALPATHLAB | Healthcare | 1.64% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| ZYDUSLIFE | Pharma | 1.40% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| BIOCON | Pharma | 1.35% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| ABBOTINDIA | Pharma | 1.25% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| KIMS | Healthcare | 1.15% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| ERIS | Pharma | 1.01% | 5 | 7 | 5 | 6 | 6 | 0/2 | +1.0% |
| JUBLPHARMA | Pharma | 0.96% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
Performance · 1.5y
Over the last 1.5 years ₹100 in the fund grew to ₹109 (+9%), vs ₹102 for Nifty 500 (+2%) and ₹101 for Nifty 50 (+1%). Its relative-strength line ended at 108 vs Nifty 50 and 107 vs Nifty 500 — above 100, sustained outperformance.